What Is Industrial Biotechnology? How to Explain Biomanufacturing to a Non-Technical Buyer

Industrial biotechnology uses living systems, mostly microorganisms, enzymes and cells, to make and process industrial goods such as chemicals, materials, fuels, food and feed ingredients. Biomanufacturing is the part of that field concerned with producing those goods at commercial scale. To explain either to a non-technical buyer, name the product and what it replaces first, then show how biology makes it possible.

A working definition and what it makes

Most people hear "biotech" and think of medicines. OECD work describes biotechnology broadly as the use of living organisms and their components to generate products and knowledge. Industrial biotechnology applies that capability to production. A microorganism, an enzyme or a cell line replaces, complements or creates an alternative to a chemical, agricultural or manufacturing pathway. The output is a product that another industry buys and uses, often without ever knowing how it was made.

Definitions vary between agencies and research bodies, and the boundaries shift with the technology. For a commercial reader the working version is simple. Biology is the production method. The product is what the customer pays for. Biomanufacturing is the operational question of making that product reliably, at volume, to specification and at a cost the market will accept.

The value lies in what biology makes possible for the customer. A scientist describes the organism and the pathway. An investor asks about the plant. A buyer asks about the product. A good explanation gives each of them the layer they need without losing the other two.

The range of outputs is wide, which is part of the communication problem. Industrial biotech companies make proteins and enzymes, platform chemicals and intermediates, polymers and fibres, fuels, food and feed ingredients, agricultural inputs such as biological crop protection, and materials that replace leather, plastic or textiles. Some make a finished product. Many make an intermediate that another manufacturer turns into something a consumer recognises.

This range explains why "biotech platform" becomes too broad for a buyer. A procurement manager at a chemicals company, a formulator at a food manufacturer and a sourcing lead at a feed mill share very little. Each of them needs the company to name its output in their terms. The broader capability can come later, once one product is understood. We cover that order in detail in industrial biotech positioning.

Who buys what industrial biotech makes?

The buyer is usually another business. A chemicals distributor buys an intermediate. A consumer goods company buys an ingredient or a material for its own products. A feed mill buys protein by the tonne against a nutritional specification. A brand owner may never buy the input directly and still shape demand by setting sourcing targets for its suppliers.

Each of these buyers already has a supplier, a price, a specification and a qualification process. The industrial biotech product enters a market that works, and it has to fit that market before it can improve on it. That means matching the incumbent on purity, consistency, form and delivery terms, then showing the advantage on top. The advantage might be price stability, a lower footprint, a new function, a shorter supply chain or independence from a volatile feedstock.

Before the production method means anything to this buyer, they need to know what the product is, where it is used, which specification matters, what it replaces, how it performs, whether it is approved for the intended use, what supply is available and what the commercial terms look like. The production method then explains why the company can deliver an advantage. The product also has to be named in the buyer's language. A formulator searches for a functional ingredient by what it does in a recipe. A chemicals buyer searches by molecule and grade. Platform vocabulary rarely appears in either search. The company that describes its output in the buyer's own terms gets found, compared and qualified sooner.

Fermentation and other production routes

Fermentation is the production route most people meet first. Microorganisms such as bacteria, yeast or fungi convert a feedstock into a target product inside a controlled vessel. In biomass fermentation, the microorganism itself becomes the product, as in many protein ingredients. In precision fermentation, an engineered organism produces a specific molecule, such as an enzyme, a dairy protein or a chemical, which is then separated and purified. Gas fermentation feeds organisms with gases such as methane, carbon dioxide or hydrogen in place of sugar.

Fermentation is one route among several. Enzymatic processing uses isolated enzymes to carry out a single chemical step, often in an existing plant. Cell culture grows animal or plant cells directly, which is the basis of cultivated meat. Other companies engineer plants or algae to make a compound in the field or in a pond.

Biomanufacturing has a translation stack

The commercial story should carry only as much biology as its reader needs. A non-technical buyer rarely needs every layer at once. A procurement team starts with the product, the specification, price and supply. A technical evaluator needs the organism, the feedstock, the titre, the yield and the purification step. An investor needs all of that plus scale-up risk, manufacturing strategy, market access and capital intensity.

Each of these is a legitimate audience, and each belongs on its own page or in its own section of the deck. A company becomes easier to understand when it organises those layers for each reader. Compressing them into the single word platform leaves every reader to do the sorting.

1. 01ProcurementProduct, specification, price and supply.
2. 02Technical evaluatorOrganism, feedstock, titre, yield and purification.
3. 03InvestorAll of the above, plus scale-up risk, manufacturing strategy, market access and capital intensity.

Each reader needs a different depth of biology. Organise the layers for each one.

Why governments treat biomanufacturing as industrial policy

In the past few years the major economies have written biomanufacturing into industrial strategy. In the United States, Executive Order 14081 launched a National Biotechnology and Biomanufacturing Initiative in 2022. The European Commission followed with its communication Building the future with nature, boosting biotechnology and biomanufacturing in the EU. The UK government published a national vision for engineering biology, which it announced as a £2 billion vision covering medicine, food and environmental protection.

Europe's current work goes further into commercial terms. The European Commission's 2026 consultation on industrial biotechnology and biomanufacturing, part of the work on a second Biotech Act, asks how the sector can build a stronger business case, including how to create demand in lead markets and improve predictability for investors. That locates the challenge beyond laboratory science. Activity is high and so is competition for capital. The 2026 Circular Bio-based Europe call attracted 272 project proposals, which the Circular Bio-based Europe Joint Undertaking reported as requesting €1.65 billion in funding. Funding and commercial success are separate outcomes, but the numbers show how much of the sector is working on the step from scientific possibility to industrial production.

For a company, this policy attention does two things. It opens funding routes, from grants to public co-investment in plants. It also raises the bar for explanation, because policy language is broad and buyers still buy one product at a time. A company that describes itself in the vocabulary of national strategy can sound important and still leave a buyer with no idea what to order. Use the policy context to explain why the timing is right, and keep the product at the centre of the pitch.

Biomanufacturing is where scale decides the story

A laboratory can show that a biological pathway produces a molecule. Manufacturing has to produce that molecule repeatedly, at useful volumes, to a quality standard and at a price a buyer will pay. That introduces a new set of questions about process stability, feedstock supply, contamination control, downstream processing, equipment, quality systems and capacity.

Scale-up takes more than a bigger fermenter. Organisms can behave differently in a large vessel. Mixing, heat transfer and oxygen supply change. Downstream separation, which may look minor at bench scale, can dominate cost at commercial volume. The operating environment changes both performance and economics, and each step up in scale needs its own evidence.

It also changes the financing. The OECD has examined financing instruments and policy levers to harness biomanufacturing for climate, biodiversity and growth, which reflects how far the capital question has moved to the centre. Once a company needs a demonstration or first commercial plant, its story expands from product and technology to plant economics, offtake, feedstock contracts, engineering partners and repeatability. That is where first-of-a-kind thinking becomes useful, and we set it out in FOAK in industrial biotech. The shift in what investors need to see is covered in why biomanufacturing scale-up changes the investor story.

A public example from Iowa

The bio-based BDO plant in Eddyville, Iowa shows how an industrial biotech product is described once it reaches commercial scale. BDO is an industrial chemical that has conventionally been made from fossil feedstocks. Cargill and HELM announced a partnership to build a $300M commercial-scale, renewable BDO facility, the first in the US, to meet growing customer demand. Genomatica, whose Geno process the plant uses, later announced that the plant had commenced operations. Qore, the business launched in Eddyville, has begun commercial production of QIRA, which it presents as a bio-based alternative to fossil-derived BDO.

Read the headline again. It names the product, BDO. It names the scale, commercial. It names the attribute, renewable. It names the reason, customer demand. The microorganism and the pathway sit behind the announcement as the reason the product exists. For a buyer of BDO, that is the correct order. The chemistry is familiar and the specification is known. The new information is the source and the supply.

Is bio-based production always lower impact?

A bio-based process has no automatic claim to a lower footprint. Feedstock, energy use, land use, water, transport, processing and waste treatment all affect the result. A fermentation process running on fossil-heavy electricity, or on a feedstock with a large land footprint, can compare poorly with an efficient conventional plant.

So avoid treating "bio" as a synonym for sustainable. Where environmental performance is part of the proposition, use a life-cycle assessment or other appropriate evidence, state the comparison, state the system boundary and say who carried out the work. Buyers with published climate targets will ask for this data, and their procurement teams will compare it against other suppliers. A clear boundary statement also protects the company when the numbers are reviewed later.

How to explain it to a non-technical buyer

Industrial biotech becomes commercially relevant when something outside the lab changes. Fossil-based inputs become volatile. Customers need lower-carbon materials. Regulation tightens. Supply security moves up the board agenda. A biological process crosses a cost threshold. Use the shift that changes this buyer's decision, and leave the other sustainability trends out of the pitch.

Then use one sentence that holds the mechanism, the product, the value, the proof and the maturity together. We use [biological process] to make [specific product] for [specific customer or application]. Compared with [current alternative], it can [supported advantage]. We have demonstrated [evidence], and the next scale step is [stage].

The sentence works because each bracket forces a decision. A team that cannot fill the product bracket has a positioning problem. A team that fills the advantage bracket with a claim it cannot support has an evidence problem. A team that leaves the stage bracket vague will be asked about it in the first meeting. The fuller version of this path, from fermentation platform to commercial product, is in building the industrial biotech story.

What to do first

Start with the product sentence above and write it for your three main audiences, a buyer, an investor and a technical partner. Keep the evidence and stage brackets identical across all three. Change only the product framing and the advantage to match what each reader needs. If the three versions contradict each other on evidence or stage, fix that before working on anything else.

Then check your homepage and deck against the order used in the Iowa announcement. The product comes first, then scale, then the attribute, then the reason, and the biology follows as the explanation. Industrial biotechnology is an industry, and its stories read best when they sound like one.

Brighter Future helps industrial biotech and biomanufacturing companies set this order through our positioning work.

Sources and further reading

• Commission seeks feedback on industrial biotechnology and biomanufacturing, European Commission, 2026
• Circular Bio-based Europe Joint Undertaking, programmes and projects, 2026
• Financing instruments and policy levers to harness biomanufacturing for climate, biodiversity and growth, OECD
• Building the future with nature, boosting biotechnology and biomanufacturing in the EU, European Commission, 2024